Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Net Operating Profit After Tax (NOPAT) 1 year YoY Change (%) for the quarter ending September 30, 2023: -8.44%

Agios Pharm Net Operating Profit After Tax (NOPAT) 1 year YoY Change (%) is -8.44% for the quarter ending September 30, 2023, a -174.94% change year over year. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Agios Pharm Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2023 was -79,881,659.62, a 15.52% change year over year.
Agios Pharm Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2022 was -94,556,529.35, a -24.13% change year over year.
Agios Pharm Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2021 was -76,173,854.55.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends